{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T06:56:52Z","timestamp":1771657012613,"version":"3.50.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2012,7,3]],"date-time":"2012-07-03T00:00:00Z","timestamp":1341273600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diabetologia"],"published-print":{"date-parts":[[2012,10]]},"DOI":"10.1007\/s00125-012-2630-1","type":"journal-article","created":{"date-parts":[[2012,7,2]],"date-time":"2012-07-02T21:44:50Z","timestamp":1341265490000},"page":"2723-2732","source":"Crossref","is-referenced-by-count":25,"title":["Low doses of anti-CD3, ciclosporin A and the vitamin D analogue, TX527, synergise to delay recurrence of autoimmune diabetes in an islet-transplanted NOD mouse model of diabetes"],"prefix":"10.1007","volume":"55","author":[{"given":"F.","family":"Baeke","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T. L.","family":"Belle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Takiishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Ding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Korf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Laureys","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Gysemans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Mathieu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,7,3]]},"reference":[{"key":"2630_CR1","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1152\/physrev.00003.2010","volume":"91","author":"TL Belle Van","year":"2011","unstructured":"Van Belle TL, Coppieters KT, von Herrath MG (2011) Type 1 diabetes: etiology, immunology, and therapeutic strategies. Physiol Rev 91:79\u2013118","journal-title":"Physiol Rev"},{"key":"2630_CR2","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1038\/nature08933","volume":"464","author":"JA Bluestone","year":"2010","unstructured":"Bluestone JA, Herold K, Eisenbarth G (2010) Genetics, pathogenesis and clinical interventions in type 1 diabetes. Nature 464:1293\u20131300","journal-title":"Nature"},{"key":"2630_CR3","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1073\/pnas.91.1.123","volume":"91","author":"L Chatenoud","year":"1994","unstructured":"Chatenoud L, Thervet E, Primo J, Bach JF (1994) Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice. Proc Natl Acad Sci U S A 91:123\u2013127","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2630_CR4","doi-asserted-by":"crossref","first-page":"2947","DOI":"10.4049\/jimmunol.158.6.2947","volume":"158","author":"L Chatenoud","year":"1997","unstructured":"Chatenoud L, Primo J, Bach JF (1997) CD3 antibody-induced dominant self tolerance in overtly diabetic NOD mice. J Immunol 158:2947\u20132954","journal-title":"J Immunol"},{"key":"2630_CR5","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1056\/NEJMoa012864","volume":"346","author":"KC Herold","year":"2002","unstructured":"Herold KC, Hagopian W, Auger JA et al (2002) Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med 346:1692\u20131698","journal-title":"N Engl J Med"},{"key":"2630_CR6","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.2337\/diabetes.54.6.1763","volume":"54","author":"KC Herold","year":"2005","unstructured":"Herold KC, Gitelman SE, Masharani U et al (2005) A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2\u00a0years after onset of type 1 diabetes. Diabetes 54:1763\u20131769","journal-title":"Diabetes"},{"key":"2630_CR7","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1056\/NEJMoa043980","volume":"352","author":"B Keymeulen","year":"2005","unstructured":"Keymeulen B, Vandemeulebroucke E, Ziegler AG et al (2005) Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med 352:2598\u20132608","journal-title":"N Engl J Med"},{"key":"2630_CR8","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1182\/blood-2009-02-204875","volume":"115","author":"B Keymeulen","year":"2010","unstructured":"Keymeulen B, Candon S, Fafi-Kremer S et al (2010) Transient Epstein-Barr virus reactivation in CD3 monoclonal antibody-treated patients. Blood 115:1145\u20131155","journal-title":"Blood"},{"key":"2630_CR9","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/S0140-6736(11)60931-8","volume":"378","author":"N Sherry","year":"2011","unstructured":"Sherry N, Hagopian W, Ludvigsson J et al (2011) Teplizumab for treatment of type 1 diabetes (Protege study): 1-year results from a randomised, placebo-controlled trial. Lancet 378:487\u2013497","journal-title":"Lancet"},{"key":"2630_CR10","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1002\/jcb.10329","volume":"88","author":"E Etten Van","year":"2003","unstructured":"Van Etten E, Decallonne B, Verlinden L, Verstuyf A, Bouillon R, Mathieu C (2003) Analogs of 1alpha,25-dihydroxyvitamin D3 as pluripotent immunomodulators. J Cell Biochem 88:223\u2013226","journal-title":"J Cell Biochem"},{"key":"2630_CR11","doi-asserted-by":"crossref","first-page":"3490","DOI":"10.1182\/blood-2005-05-2044","volume":"106","author":"G Penna","year":"2005","unstructured":"Penna G, Roncari A, Amuchastegui S et al (2005) Expression of the inhibitory receptor ILT3 on dendritic cells is dispensable for induction of CD4+FOXP3+ regulatory T cells by 1,25-dihydroxyvitamin D3. Blood 106:3490\u20133497","journal-title":"Blood"},{"key":"2630_CR12","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.2337\/diabetes.51.5.1367","volume":"51","author":"S Gregori","year":"2002","unstructured":"Gregori S, Giarratana N, Smiroldo S, Uskokovic M, Adorini L (2002) A 1alpha,25-dihydroxyvitamin D(3) analog enhances regulatory T cells and arrests autoimmune diabetes in NOD mice. Diabetes 51:1367\u20131374","journal-title":"Diabetes"},{"key":"2630_CR13","doi-asserted-by":"crossref","first-page":"6071","DOI":"10.4049\/jimmunol.0804064","volume":"182","author":"M Ghoreishi","year":"2009","unstructured":"Ghoreishi M, Bach P, Obst J, Komba M, Fleet JC, Dutz JP (2009) Expansion of antigen-specific regulatory T cells with the topical vitamin d analog calcipotriol. J Immunol 182:6071\u20136078","journal-title":"J Immunol"},{"key":"2630_CR14","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.jaut.2004.06.004","volume":"23","author":"AG Halteren van","year":"2004","unstructured":"van Halteren AG, Tysma OM, van Etten E, Mathieu C, Roep BO (2004) 1alpha,25-dihydroxyvitamin D3 or analogue treated dendritic cells modulate human autoreactive T cells via the selective induction of apoptosis. J Autoimmun 23:233\u2013239","journal-title":"J Autoimmun"},{"key":"2630_CR15","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1196\/annals.1337.030","volume":"1037","author":"E Etten van","year":"2004","unstructured":"van Etten E, Dardenne O, Gysemans C, Overbergh L, Mathieu C (2004) 1,25-Dihydroxyvitamin D3 alters the profile of bone marrow-derived dendritic cells of NOD mice. Ann N Y Acad Sci 1037:186\u2013192","journal-title":"Ann N Y Acad Sci"},{"key":"2630_CR16","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.beem.2011.04.009","volume":"25","author":"TL Belle Van","year":"2011","unstructured":"Van Belle TL, Gysemans C, Mathieu C (2011) Vitamin D in autoimmune, infectious and allergic diseases: a vital player? Best Pract Res Clin Endocrinol Metab 25:617\u2013632","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"2630_CR17","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.2337\/diabetes.41.11.1491","volume":"41","author":"C Mathieu","year":"1992","unstructured":"Mathieu C, Laureys J, Sobis H, Vandeputte M, Waer M, Bouillon R (1992) 1,25-Dihydroxyvitamin D3 prevents insulitis in NOD mice. Diabetes 41:1491\u20131495","journal-title":"Diabetes"},{"key":"2630_CR18","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1210\/en.136.3.866","volume":"136","author":"C Mathieu","year":"1995","unstructured":"Mathieu C, Waer M, Casteels K, Laureys J, Bouillon R (1995) Prevention of type I diabetes in NOD mice by nonhypercalcemic doses of a new structural analog of 1,25-dihydroxyvitamin D3, KH1060. Endocrinology 136:866\u2013872","journal-title":"Endocrinology"},{"key":"2630_CR19","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1007\/BF00403372","volume":"37","author":"C Mathieu","year":"1994","unstructured":"Mathieu C, Waer M, Laureys J, Rutgeerts O, Bouillon R (1994) Prevention of autoimmune diabetes in NOD mice by 1,25 dihydroxyvitamin D3. Diabetologia 37:552\u2013558","journal-title":"Diabetologia"},{"key":"2630_CR20","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1046\/j.1365-2249.2002.01825.x","volume":"128","author":"C Gysemans","year":"2002","unstructured":"Gysemans C, van Etten E, Overbergh L et al (2002) Treatment of autoimmune diabetes recurrence in non-obese diabetic mice by mouse interferon-beta in combination with an analogue of 1alpha,25-dihydroxyvitamin-D3. Clin Exp Immunol 128:213\u2013220","journal-title":"Clin Exp Immunol"},{"key":"2630_CR21","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1210\/en.139.1.95","volume":"139","author":"KM Casteels","year":"1998","unstructured":"Casteels KM, Mathieu C, Waer M et al (1998) Prevention of type I diabetes in nonobese diabetic mice by late intervention with nonhypercalcemic analogs of 1,25-dihydroxyvitamin D3 in combination with a short induction course of cyclosporin A. Endocrinology 139:95\u2013102","journal-title":"Endocrinology"},{"key":"2630_CR22","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1097\/00007890-199805150-00014","volume":"65","author":"K Casteels","year":"1998","unstructured":"Casteels K, Waer M, Laureys J et al (1998) Prevention of autoimmune destruction of syngeneic islet grafts in spontaneously diabetic nonobese diabetic mice by a combination of a vitamin D3 analog and cyclosporine. Transplantation 65:1225\u20131232","journal-title":"Transplantation"},{"key":"2630_CR23","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1111\/j.1398-9995.2009.02054.x","volume":"64","author":"C Brandt","year":"2009","unstructured":"Brandt C, Pavlovic V, Radbruch A, Worm M, Baumgrass R (2009) Low-dose cyclosporine A therapy increases the regulatory T cell population in patients with atopic dermatitis. Allergy 64:1588\u20131596","journal-title":"Allergy"},{"key":"2630_CR24","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1182\/blood-2006-01-0329","volume":"108","author":"R Zeiser","year":"2006","unstructured":"Zeiser R, Nguyen VH, Beilhack A et al (2006) Inhibition of CD4+CD25+ regulatory T cell function by calcineurin-dependent interleukin-2 production. Blood 108:390\u2013399","journal-title":"Blood"},{"key":"2630_CR25","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.immuni.2005.08.002","volume":"23","author":"LK Shoda","year":"2005","unstructured":"Shoda LK, Young DL, Ramanujan S et al (2005) A comprehensive review of interventions in the NOD mouse and implications for translation. Immunity 23:115\u2013126","journal-title":"Immunity"},{"key":"2630_CR26","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.2337\/db08-0882","volume":"58","author":"APR Sutherland","year":"2009","unstructured":"Sutherland APR, van Belle T, Wurster AL et al (2009) Interleukin-21 is required for the development of Type 1 diabetes in NOD mice. Diabetes 58:1144\u20131155","journal-title":"Diabetes"},{"key":"2630_CR27","first-page":"33","volume":"14","author":"L Overbergh","year":"2003","unstructured":"Overbergh L, Giulietti A, Valckx D, Decallonne R, Bouillon R, Mathieu C (2003) The use of real-time reverse transcriptase PCR for the quantification of cytokine gene expression. J Biomol Tech 14:33\u201343","journal-title":"J Biomol Tech"},{"key":"2630_CR28","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1038\/nri2134","volume":"7","author":"L Chatenoud","year":"2007","unstructured":"Chatenoud L, Bluestone JA (2007) CD3-specific antibodies: a portal to the treatment of autoimmunity. Nat Rev Immunol 7:622\u2013632","journal-title":"Nat Rev Immunol"},{"key":"2630_CR29","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/j.1365-2567.2009.03217.x","volume":"130","author":"DS Mehta","year":"2010","unstructured":"Mehta DS, Christmas RA, Waldmann H, Rosenzweig M (2010) Partial and transient modulation of the CD3-T cell receptor complex, elicited by low-dose regimens of monoclonal anti-CD3, is sufficient to induce disease remission in non-obese diabetic mice. Immunology 130:103\u2013113","journal-title":"Immunology"},{"key":"2630_CR30","first-page":"A90","volume":"60","author":"F Waldron-Lynch","year":"2011","unstructured":"Waldron-Lynch F, Henegariu O, Esplugues E et al (2011) Teplizumab treatment induces migration of human T regulatory lymphocytes to the small intestine in vivo. Diabetes 60:A90","journal-title":"Diabetes"},{"key":"2630_CR31","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1038\/nature10228","volume":"475","author":"E Esplugues","year":"2011","unstructured":"Esplugues E, Huber S, Gagliani N et al (2011) Control of TH17 cells occurs in the small intestine. Nature 475:514\u2013518","journal-title":"Nature"},{"key":"2630_CR32","first-page":"1806","volume":"118","author":"P Monti","year":"2008","unstructured":"Monti P, Scirpoli M, Maffi P et al (2008) Islet transplantation in patients with autoimmune diabetes induces homeostatic cytokines that expand autoreactive memory T cells. J Clin Invest 118:1806\u20131814","journal-title":"J Clin Invest"},{"key":"2630_CR33","first-page":"1625","volume":"118","author":"T Belle Van","year":"2008","unstructured":"Van Belle T, von Herrath M (2008) Immunosuppression in islet transplantation. J Clin Invest 118:1625\u20131628","journal-title":"J Clin Invest"},{"key":"2630_CR34","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/S0065-2776(08)00804-3","volume":"100","author":"S Tsai","year":"2008","unstructured":"Tsai S, Shameli A, Santamaria P (2008) CD8+ T cells in type 1 diabetes. Adv Immunol 100:79\u2013124","journal-title":"Adv Immunol"},{"key":"2630_CR35","doi-asserted-by":"crossref","first-page":"867","DOI":"10.2337\/db10-1157","volume":"60","author":"HM McGuire","year":"2011","unstructured":"McGuire HM, Walters S, Vogelzang A et al (2011) Interleukin-21 is critically required in autoimmune and allogeneic responses to islet tissue in murine models. Diabetes 60:867\u2013875","journal-title":"Diabetes"},{"key":"2630_CR36","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1038\/39614","volume":"389","author":"H Groux","year":"1997","unstructured":"Groux H, O'Garra A, Bigler M et al (1997) A CD4+ T cell subset inhibits antigen-specific T cell responses and prevents colitis. Nature 389:737\u2013742","journal-title":"Nature"},{"key":"2630_CR37","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1038\/nm924","volume":"9","author":"M Belghith","year":"2003","unstructured":"Belghith M, Bluestone JA, Barriot S, Megret J, Bach JF, Chatenoud L (2003) TGF-beta-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes. Nat Med 9:1202\u20131208","journal-title":"Nat Med"},{"key":"2630_CR38","doi-asserted-by":"crossref","first-page":"4525","DOI":"10.4049\/jimmunol.174.8.4525","volume":"174","author":"AP Kohm","year":"2005","unstructured":"Kohm AP, Williams JS, Bickford AL et al (2005) Treatment with nonmitogenic anti-CD3 monoclonal antibody induces CD4+ T cell unresponsiveness and functional reversal of established experimental autoimmune encephalomyelitis. J Immunol 174:4525\u20134534","journal-title":"J Immunol"},{"key":"2630_CR39","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/nrendo.2009.275","volume":"6","author":"L Chatenoud","year":"2010","unstructured":"Chatenoud L (2010) Immune therapy for type 1 diabetes mellitus: what is unique about anti-CD3 antibodies? Nat Rev Endocrinol 6:149\u2013157","journal-title":"Nat Rev Endocrinol"},{"key":"2630_CR40","doi-asserted-by":"crossref","first-page":"6205","DOI":"10.4049\/jimmunol.165.11.6205","volume":"165","author":"PA Carpenter","year":"2000","unstructured":"Carpenter PA, Pavlovic S, Tso JY et al (2000) Non-Fc receptor-binding humanized anti-CD3 antibodies induce apoptosis of activated human T cells. J Immunol 165:6205\u20136213","journal-title":"J Immunol"},{"key":"2630_CR41","doi-asserted-by":"crossref","first-page":"4338","DOI":"10.4049\/jimmunol.150.10.4338","volume":"150","author":"S Wesselborg","year":"1993","unstructured":"Wesselborg S, Janssen O, Kabelitz D (1993) Induction of activation-driven death (apoptosis) in activated but not resting peripheral blood T cells. J Immunol 150:4338\u20134345","journal-title":"J Immunol"},{"key":"2630_CR42","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.4049\/jimmunol.1100713","volume":"187","author":"C Penaranda","year":"2011","unstructured":"Penaranda C, Tang Q, Bluestone JA (2011) Anti-CD3 therapy promotes tolerance by selectively depleting pathogenic cells while preserving regulatory T cells. J Immunol 187:2015\u20132022","journal-title":"J Immunol"},{"key":"2630_CR43","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.jsbmb.2004.03.017","volume":"89\u201390","author":"E Etten van","year":"2004","unstructured":"van Etten E, Decallonne B, Bouillon R, Mathieu C (2004) NOD bone marrow-derived dendritic cells are modulated by analogs of 1,25-dihydroxyvitamin D3. J Steroid Biochem Mol Biol 89\u201390:457\u2013459","journal-title":"J Steroid Biochem Mol Biol"},{"key":"2630_CR44","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1210\/en.2004-1322","volume":"146","author":"CA Gysemans","year":"2005","unstructured":"Gysemans CA, Cardozo AK, Callewaert H et al (2005) 1,25-Dihydroxyvitamin D3 modulates expression of chemokines and cytokines in pancreatic islets: implications for prevention of diabetes in nonobese diabetic mice. Endocrinology 146:1956\u20131964","journal-title":"Endocrinology"}],"container-title":["Diabetologia"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-012-2630-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00125-012-2630-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-012-2630-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,24]],"date-time":"2023-06-24T01:20:15Z","timestamp":1687569615000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00125-012-2630-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,7,3]]},"references-count":44,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2012,10]]}},"alternative-id":["2630"],"URL":"https:\/\/doi.org\/10.1007\/s00125-012-2630-1","relation":{},"ISSN":["0012-186X","1432-0428"],"issn-type":[{"value":"0012-186X","type":"print"},{"value":"1432-0428","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,7,3]]}}}